Table 4.
Response rates and duration of responses for skin treatments for MF/SS.
| Treatment | Staging | Overall response (%) | Complete response (%) | Response duration | References |
|---|---|---|---|---|---|
| Corticosteroid | T1–T2 | 82–94 | 25–63 | RD: 9 months | 9 |
| Nitrogen mustard | T1–T2 | 58.5–93 | 13.8–80 | – | 10, 11 |
| Carmustine | T1–T2 | 84–98 | 47–86 | – | 12 |
| Bexarotene | T1–T2 | 54–63 | 10–21 | RD: 25 months | 13 |
| Imiquimod | T1–T2 | 80 | 45 | – | 14 |
| Resiquimod | T1–T2 | 75 | 33 | – | 15 |
| NB-UVB | T1–T2 | – | 54–91 | RD: 22 months | 16 |
| PUVA | T1–T2 | – | 65–85 | RD: 23 months | 16 |
| Localized RT | un. MF, 30Gy | 100 | – | DFS, 5 years: 86% | 19 |
| Ia–III, 9–45Gy | 94 | 88 | PFS, 5 years: 85% | 17 | |
| Total skin irradiation with electrons | T1–T2, 36Gy | 95 | 85–88 | PFS, 5 years: 50% | 20 |
| Ia–III, 12Gy | 88 | 27 | RD: 70.7 weeks | 21 |
RD, Response Duration; PFS, Progression-Free Survival; DFS, Disease-Free Survival; NB-UVB, narrow-band UVB; RT, Radiotherapy; Gy, Gray; un. MF, unilesional mycosis fungoides.